Didanosine-induced Disorders of Glucose Tolerance
To the Editors: In their review, Pandit and colleagues (1) compiled a comprehensive list of drugs capable of inducing disorders of glucose tolerance. Some drugs mentioned, such as pentamidine, trimethoprim-sulfamethoxazole, corticosteroids, dapsone, rifampin, ganciclovir, and octreotide, are commonly used for the treatment of patients with human immunodeficiency virus (HIV) infection. Didanosine (ddl), an increasingly used antiretroviral agent, can also induce hyperglycemia and may occasionally cause overt diabetes mellitus.
The pancreatic toxicity of ddl is well established (2) (3) (4) . Some authors have reported reversible hyperglycemia or development of diabetes with and without concurrent elevation of amylase or lipase levels in a substantial proportion of their patients treated with ddl (3, 4) .
After having observed the consecutive development of diabetes and pancreatitis in one of our ddl-treated patients, we prospectively followed 12 patients who at the beginning of ddl treatment had normal glucose tolerance (venous plasma glucose concentrations <200 mg/dL after challenge with 75 g of glucose). Six developed impaired glucose tolerance (glucose levels >200 mg/dL after glucose challenge), which reversed on stopping ddl.
We and others (3) have observed that alterations in glucose metabolism may precede the onset of pancreatitis. We hope that future prospective studies clarify whether regular screening of ddl-treated patients for new manifestations of alterations of glucose tolerance contributes to the identification of those at risk for the development of potentially fatal pancreatitis. Until this issue has been resolved, ddl-treated patients who develop altered glucose metabolism should be monitored closely for manifestations of pancreatitis. Overt diabetes could indicate pancreatic injury due to ddl and probably should lead to the drug's discontinuance.
Because ddl has also been reported to cause substantial hepatotoxicity with subsequent development of hypoglycemia (5) , it should be included in future reviews of drug-induced disorders of glucose tolerance.
In response: We thank Dr. Albrecht and colleagues for their interesting observation on the diabetogenic effect of ddl. Further studies should help elucidate the exact mechanisms of action of this agent on glucose tolerance.
Manjula Pandit, MD Veterans Affairs Medical Center Louisville, KY 40206

Quantifying Lymphocytes in Bronchoalveolar Lavage Fluid
To the Editors: In their recent article, Roberts and colleagues (1) reported cell counts and differentials in specimens obtained by bronchoalveolar lavage before and after radiotherapy in 17 women with breast cancer. The authors observed increases in the total number and percentage of lymphocytes after irradiation, especially in those who developed clinical pneumonitis. They concluded that a generalized lymphocytemediated hypersensitivity reaction may play a role in the development of radiation pneumonitis.
The authors did not, however, provide an explanation for the striking elevation in the mean percentage of lymphocytes in bronchoalveolar lavage specimens obtained before irradiation. In normal bronchoalveolar lavage fluid, lymphocytes typically account for fewer than 15% of the total cells. Measurements using the millipore filter method may be slightly higher (about 35% more than in cytocentrifuge preparations) (2) . This differential is not sufficient to explain the findings of a mean bronchoalveolar lavage lymphocyte percentage of 34.5% in patients before irradiation.
We need to know the range of normal values for bronchoalveolar lavage cell count and differential in the laboratory that did the cell counts to determine whether an alveolar lymphocytosis was present before irradiation or if what appear to be elevated values are within that laboratory's normal range. Oth-erwise, the significance of the increase in bronchoalveolar lavage lymphocytes after irradiation and their role in radiation pneumonitis are less clear. To the Editors: I read with great interest the recent article by Roberts and colleagues (1) . Of concern was the marked lymphocytosis present in lavage fluid before irradiation, as well as the slightly elevated cell count. The patients had an increased total cell count (22.4 x 10 6 cells with 61% macrophages, 34.5% lymphocytes, and 4% neutrophils). Such an increase in cellularity and prominent lymphocytosis represents a markedly abnormal baseline. In studies reviewed by the Bronchoalveolar Lavage Cooperative Group Steering Committee, total cell counts were generally less than 16 x 10 6 cells in nonsmoking patients when the lavage volume was less than or equal to 150 mL. The percentage of lymphocytes in bronchoalveolar lavage fluid in normal persons is universally less than 20% (10% on average). In normal smokers, the total cell count is generally increased on the order of 30 to 50 x 10 6 cells, with lymphocytes not expected to exceed 8% (2) .
This finding suggests a baseline lymphocytic alveolitis before any radiotherapy that was apparently exacerbated by a course of unilateral thoracic irradiation.
Determining the cause of this baseline abnormality in these patients is essential before concluding anything about the true effect of unilateral thoracic radiation. These findings could be associated with methotrexate pneumonitis (3) or toxicity from another chemotherapeutic agent, or they could be secondary to extrinsic allergic alveolitis (4) related to a humidifier system or related to another antigen in the local environment. Studying bronchoalveolar lavage fluid obtained before chemotherapy, as well as screening the patients for hypersensitivity pneumonitis, would be helpful to clarify the underlying disorder.
In response: Both letters comment on the apparently high percentage of lymphocytes in the preradiotherapy group (1). These lymphocyte percentages are due to important methodologic variables and not to another underlying abnormality. In our study, the pre-radiotherapy total cell number (22.4 ± 18.9 million) and proportion of lymphocytes (34.5% ± 13.4%) before radiotherapy did not differ significantly from the values for normal persons (34.7 ± 19 million and 29.1%) ± 12.9%?, respectively) (2), which we have determined in other studies (2, 3) . These letters do highlight an important common misconception about lymphocyte counts in bronchoalveolar lavage samples that is based on data from the inaccurate method for cell quantification, cytocentrifuge preparation, which is widely used because of its simplicity, because of the large body of data gathered using this method, and because of the absence of a need to justify the use of alternate nonstandard methods. Although the cytocentrifuge method appears to be relatively accurate for the enumeration of neutrophils, Saltini and colleagues (4) have shown that it markedly underestimates lymphocyte numbers. Even worse, the error is not predictable, obviating the use of any correction factor (4). These factors have led to the commonly held but inaccurate view that normal bronchoalveolar lavage fluid contains very low lymphocyte numbers.
Our experience (1-3) is consistent with that of Saltini and coworkers (4), and we use their suggested millipore filter method. Further, findings from flow cytometric evaluation, which is unlikely to distort relative cell numbers, are consistent with the percentage of lymphocytes present using the millipore filter (unpublished data). A recent article (5) concerning the distribution of cytocentrifuge-determined lavage cellularity data in large numbers of normal volunteers reinforces this point. Merchant and colleagues (5) found that the proportion of neutrophils and eosinophils, cells that are not subjected to the same errors during the cytocentrifugation procedure, follow a Poisson distribution. Lymphocyte and the inversely related macrophage proportions, however, failed to show either a normal or Poisson distribution. A random error of large magnitude generated by the cytocentrifuge counting method would certainly account for this otherwise unexpected and unexplained failure.
We strongly suggest that alternate methods to the cytocentrifuge should be used for determining the proportion of lymphocytes and macrophages in bronchoalveolar lavage fluid. 
Effect of Inhaled Steroids on the Course of Asthma
To the Editors: Kerstjens and associates (1) found no effect after 18 months of inhaled steroids on the decrease in forced expiratory volume in 1 second (FEV^ in a randomized controlled trial that included a similar number of patients treated with inhaled steroids. However, Dompeling and coworkers (2) reported a significantly slower rate of decline in prebronchodilator FEV! during 18 months of inhaled corticosteroid treatment in 56 patients with asthma (n = 28) or chronic obstructive pulmonary disease (COPD) (n = 28), compared with the same group before initiation of inhaled steroid treatment. They interpreted this result as evidence that inhaled corticosteroids "slowed the unfavorable course of asthma or COPD seen with bronchodilator therapy alone." It is well established that therapy with inhaled corticosteroids improves asthma symptoms. The study of Dompeling and colleagues (2) showed decreased bronchial hyper-responsiveness in asthmatics and alleviation of symptoms and a decrease in the number of exacerbations in both asthmatics and patients with COPD, thus supporting this role for inhaled steroids. I suggest that the improvements in prebronchodilator FEVj found in their study probably relate to these changes in bronchial hyper-reactivity, symptoms and exacerbations of asthma and COPD, rather than to the irreversible inflammatory damage that presumably underlies accelerated declines in maximal FEV X noted among asthmatic patients. In response: To determine whether inhaled corticosteroid treatment prevents the accelerated decline in FEV! observed during bronchodilator therapy alone, patients must be observed during a prolonged bronchodilator treatment period with and without inhaled steroids. This was not done in the study by Kerstjens and colleagues (1), a randomized controlled trial of bronchodilator therapy with or without inhaled corticosteroids. Kerstjens and associates reported that patients who used only the /3 2 -agonist had an FEV! decline of 64 mL per year and that the patients who used the combination of the j8 2 -agonist and the inhaled steroid had an FEVj decline of 33 mL per year. It would have been interesting to follow the patients who received the /3 2 -agonist alone after the addition of an inhaled steroid.
David L. Hahn, MD
As to the difference between prebronchodilator and postbronchodilator FEV! slope, the redrawn figure in which the postbronchodilator FEV! values are included is interesting. We agree that no difference was seen between the postbronchodilator value before and during corticosteroid therapy, and even a nonsignificant opposite trend (-98 mL/year compared with -120 mL/year) resulted in the paradoxical extrapolation. We observed a significant improvement, however, in postbronchodilator FEVj during the first 6 months of treatment ( + 105 mL/year), which seemed to occur only in patients with asthma (+201 mL/year) and not in patients with COPD (-5 mL/year).
We agree completely that the effects of steroid treatment were much more pronounced during prebronchodilator treatment than during postbronchodilator treatment. Indeed, this study proved that the prebronchodilator slope did not indicate an irreversible change in lung function: The steep average prebronchodilator decline of 320 mL during the 2-year bronchodilator treatment period was followed by an increase of 229 mL during the first 6 months of steroid treatment, indicating that at least 72% of this loss seems to be reversible. However, to some extent, this was true for the postbronchodilator change: The average postbronchodilator decline of 196 mL during the 2-year bronchodilator treatment period was followed by an increase of 53 mL during the first 6 months of steroid treatment, indicating that at least 27% of this loss seems to be reversible.
Apart from theoretical considerations, thus far, only the prebronchodilator FEVj slope has been shown to be a predictor of asthma mortality (2). We are not aware of any studies that investigated the postbronchodilator FEV, slope as an indicator of disease severity.
Finally, we should emphasize that extrapolations of observations made during only 2 to 4 years should be interpreted with extreme caution. As we mentioned (3), these extrapolations are a simplification. It can be questioned whether a linear model (as used in the extrapolations of ourselves and in this drawn figure) is adequate to predict the course of lung function over 10 to 20 years.
Isolated Right Ventricular Infarction
To the Editors: Kahn and colleagues (1) described two patients with isolated right ventricular infarction due to a lesion in a nondominant right coronary artery who were treated with angioplasty. Both presented with normal 12-lead electrocardiograms, although the second developed atrial fibrillation.
We previously described a similar patient who presented with atrial fibrillation and isolated ST-segment elevation in lead VI with inferolateral ST depression (2). Isolated right ventricular infarction was confirmed by creatine kinase elevation, echocardiography, and right-heart catheterization. Post-infarction angina led to cardiac catheterization, which showed a codominant circulation with an anomalous right coronary artery arising from the left coronary cusp. Coronary angioplasty was done successfully on an 85% proximal stenosis of the right coronary artery, and the sinoatrial nodal artery appeared to originate distal to the lesion.
We agree that isolated right ventricular infarction may be an under-recognized entity because patients may have normal or unusual electrocardiographic findings. Atrial fibrillation has been described previously in patients with isolated right ventricular infarction (3), as might be expected from the usual origin of the sinus nodal artery from the right coronary artery. The combination of symptoms compatible with infarction, new-onset atrial fibrillation, and a normal 12-lead electrocardiogram or isolated ST elevation in lead VI would suggest isolated right ventricular infarction. Echocardiography and right-sided electrocardiographic leads may aid in diagnosis, as may right-heart catheterization in patients with hemodynamic compromise. The increased availability of angioplasty will undoubtedly lead to such treatment if the condition is recognized.
David M. Zientek, MD Austin Cardiology Consultants Austin, TX 78705
Carl E. Eybel, MD Associates in Cardiology, Ltd. Chicago, IL 60612
Reversible Marked Splenomegaly in Pernicious Anemia
To the Editors: Pernicious anemia is characterized by macrocytosis, neuropathy, and mucosal atrophy of the gastrointestinal tract, but marked splenomegaly is not considered to be a characteristic. We describe a patient with a marked enlargement of the spleen that resolved after vitamin B 12 therapy.
In September 1991, a 46-year-old white man presented with fatigue. Physical findings included pallor and splenomegaly palpable at 8 cm below the left costal margin. Laboratory findings showed pancytopenia and macrocytosis. The patient had a leukocyte count of 2.0 x 10 9 , with a normal differential; a hemoglobin concentration of 57 g/L; a mean corpuscular volume of 119 fL; a platelet count of 141 x 10 9 /L; a total bilirubin of 2.1 mg/dL, with a normal direct fraction (other liver function tests were normal); and a lactic dehydrogenase level of 2940 U/L. A peripheral blood smear contained oval macrocytes and hypersegmented neutrophils, and the patient's bone marrow showed characteristic megaloblastic changes. The diagnosis was confirmed with an undetectable vitamin B 12 , normal serum folate, positive intrinsic factor antibody, and Schilling test. The splenomegaly and pancytopenia resolved 3 months after initiation of vitamin B 12 therapy.
In the first half of the century, the reported incidence of splenomegaly in pernicious anemia varied from 3% to 45% (1-3) , and the size ranged from 3 to 14 cm below the left costal margin (3) . Palpable splenomegaly in patients with pernicious anemia reportedly declined after the introduction of "liver therapy" in 1926 (1, 4) . Subsequently, Bigg (2) reported an incidence of 3% (6 of 200 patients). Of the 6 patients, 2 had no other condition that could account for the observed splenomegaly. In one of these patients, the spleen size regressed with treatment.
Thus, splenomegaly is probably a consistent feature of protracted, untreated pernicious anemia, which is now rare due to earlier recognition and institution of specific replacement therapy. Unlike in a previously reported case (5), the splenomegaly seen in our patient was totally reversed with vitamin B 12 therapy. We conclude therefore that although marked splenomegaly may occur in pernicious anemia, it is both rare and reversible with treatment.
Silicone Breast Implants and Atypical Autoimmune Disease
To the Editors: Bridges and associates (1) have provided timely documentation of clinical and immunologic features in women with rheumatologic complaints after silicone augmentation mammoplasty. Human adjuvant disease is a connective tissue disorder that sometimes meets American College of Rheumatology criteria for the diagnosis of systemic lupus erythematosus, rheumatoid arthritis, progressive systemic sclerosis, mixed connective tissue disease, or unclassified rheumatic syndromes (1-5) and occurs 6 to 15 years after implantation mammoplasty (1) (2) (3) (4) (5) . We describe a 39-year-old white woman who had augmentation mammoplasty in 1982 and revision of a ruptured left implant in 1989 and who developed a skin rash and eye inflammation in the fall of 1990. Her skin lesions fit the description of those reported by Bridges and colleagues as an intermediate cutaneous scleroderma. Laboratory testing was noteworthy for a positive antinuclear antibody test result (titer, 1:320) using HEp-2 cells as the tissue substrate and a negative result for dsDNA by indirect immunofluorescence using Crithidia lucilae as substrate. Skin and eye inflammation persisted for months, despite therapy with topical skin and eye steroid preparations but resolved within 10 days of removal of the intact breast implants.
The rapid improvement after intact implant removal strongly suggests an association between her scleroderma-like reaction and the silicone breast implants. The episcleritis and conjunctivitis have not been described as a manifestation of this syndrome but clearly are seen in several rheumatic diseases. We agree that atypical autoimmune illness may occur in some women after placement of silicone breast implants (1). 
Spiera
H. Scleroderma after silicone augmentation mammoplasty. JAMA. 1988;260:236-8. 3. Brozena SJ, Fenske NA, Cruse CW, Espinoza CG, Vasey FB, Ger
Importance of Renal Artery Stenosis in Normotensive Patients
To the Editors: In their recent review of atherosclerotic renovascular disease, Rimmer and Gennari (1) point out that hypertension is not a sensitive marker of renal artery stenosis. Several studies were cited showing that among normotensive persons undergoing angiography for nonrenal indications, an important minority have anatomically significant renal artery stenosis. The important issue here, however, is not whether renal artery stenosis can occur in the absence of hypertension, but rather whether renal artery narrowing can be severe enough to cause renal failure without raising blood pressure. In the study by Harding and colleagues (2) , in which 15% of 1235 patients undergoing coronary angiography were found to have unsuspected radiographically significant renal artery stenosis, the mean serum creatinine level was normal in patients with unilateral and those with bilateral disease. This finding suggests that, in the absence of hypertension, many of these angiographically significant renal artery lesions may be functionally insignificant.
As Rimmer and Gennari point out, the risks associated with diagnostic and therapeutic intervention are not trivial in those persons most likely to be affected by atherosclerosis. In deciding whether to intervene invasively in normotensive patients with vascular disease and renal failure, it would be very helpful to know if renal artery stenosis ever causes clinically important renal failure without causing hypertension.
In response: To answer Dr. Spital's question with complete confidence would require data that are not currently available. Certainly, individual patients with impaired renal function due to renal artery stenosis can present without hypertension (see case 9 from Messina and coworkers [1] ). In our experience, the observed normal or low blood pressure is most likely due to the use of drugs with antihypertensive effects for the treatment of angina or heart failure, although in some cases it appears to be due to severely depressed cardiac output. Most of these patients have a history of hypertension, but some do not.
We agree that renal failure resulting solely from renovascular disease would be unlikely to develop without hypertension in the patient who takes no medications and has an otherwise normal cardiovascular system. In experimental unilateral renal artery stenosis, however, hypertension can resolve. If such a state exists in a patient who is treated with converting enzyme inhibitors, calcium-entry blockers, or beta-blockers for a comorbid condition, hypertension may be lost as an indicator of progressive vascular disease when a contralateral renal artery lesion develops. We believe that unexplained progressive renal insufficiency in a patient with diffuse vascular disease should raise the question of renal artery stenosis whether or not hypertension is present.
We feel that the data from the study by Harding and colleagues (2) support the view that, within the group of patients with proven atherosclerotic vascular disease, a rather large number are "at risk" for renal disease due to renal artery stenosis. It is important to emphasize that even if renovascular disease were responsible for 15% of end-stage renal disease in the United States, this outcome would still be relatively rare in the general population (incidence, 27 cases per million). This observation, plus the lack of a difference in average renal function in the groups with and without renovascular disease noted by Dr. Spital, suggests that the disease uncommonly progresses to renal failure. Although we recommend intervention when renal insufficiency is progressive, we hope we conveyed our view that, in the absence of progressive renal disease or uncontrolled hypertension, the physiologic and prognostic importance of renal artery stenoses is uncertain, and we do not recommend trying to find or treat such lesions.
Jeffrey M. Rimmer, MD F. John Gennari, MD University of Vermont College of Medicine Burlington, VT
To the Editors: Dr. Garnick discussed the early treatment of metastatic prostate cancer, total androgen blockade, and the cost of 1 year of flutamide therapy. He stated that 165 000 new cases of prostate cancer are expected to be diagnosed in the United States in 1993, with 25% of patients presenting with stage D 2 disease. The early use of total androgen blockade is gaining widespread acceptance in such patients, but it should be noted that the use of flutamide for 1 year as part of total androgen blockade will cost more than 100 million dollars in this country alone. Unfortunately, the therapeutic advantage achieved with total androgen blockade compared with hormonal monotherapy is marginal at best ( [1] [2] [3] [4] [5] [6] In response: Dr. Hahn is correct about the substantial controversy relating to the advisability and effectiveness of prostate cancer screening programs. Some patients may benefit from screening by early detection and treatment, whereas others should be left untreated.
My comment regarding efforts at earlier diagnosis of prostate cancer was not intended to imply that all cancers require treatment. Rather, potential curative therapy must be considered in high-risk patients in whom local or metastatic extension is likely.
Several end points are helpful in evaluating benefits from earlier intervention of localized prostate cancer. Regardless of overall survival benefit, preventing the complications of local recurrence, urinary tract obstruction, and other signs and symptoms of urinary dysfunction from an enlarging gland is important. Prevention of local tumor extension may or may not justify a radical prostatectomy. Future studies should identify histologic grade, differentiation, the extent of a primary tumor within the gland, and other variables to assist in a more discriminate therapeutic plan. The letter from Drs. Bilgrami and Greenberg deserves special comment. The current data support the widespread use of flutamide as part of total androgen blockade in stage D 2 prostate cancer patients. The largest randomized controlled study of 603 patients by the National Cancer Institute (NCI) showed a 26% increased survival rate in the flutamide-plus-leuprolide group compared with the leuprolide-placebo group (1), especially in patients with minimal disease and small tumor burden. Quality of life, including decreased pain and improved diseasefree progression, was also better. Another study supported the addition of flutamide to either luteinizing hormone-releasing hormone analog therapy or orchiectomy (2) . Studies that have not shown a benefit of total androgen blockade have had methodologic deficiencies such as the inclusion of other than stage D 2 patients, small patient numbers, and no double-blinding or placebo control (3, 4) .
The cost of flutamide compared with that of other antineoplastic agents is modest. In the NCI Intergroup Study (1), the marginal cost of adding flutamide was estimated to be $7500 over a 3-year period. The increase in years of life saved was 7.3 months or 0.61 years. The cost per year of life saved by adding flutamide is $12 300 ($7500 divided by 0.61). This compares favorably with other health investments, such as the implantable defibrillator, estrogen replacement therapy for postmenopausal symptoms, and continuous ambulatory peritoneal dialysis. Cost-effectiveness is greater if the analysis is restricted to patients treated with flutamide who had minimal disease and an excellent performance status.
Marc B. Garnick, MD
Genetics Institute, Inc. Cambridge, MA 02140
